MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive: Finally, maintenance of ERK1/2 activation was detected in JULMK1R and LamaR CML cells treated with ponatinib as it is the case in K562R cells (Figure 3B and [9]).